Skip to main content
. 2016 Jun 14;8(3):221–232. doi: 10.5114/jcb.2016.60590

Table 2.

The mean value and standard deviation of cumulative biological equivalent dose EQD2 (D90 and D100) and V100 at the GTV, HRCTV-pv, and IRCTV-pv of the 30 patients

Parameter Mean ± SD (simple size = 30; df = 29)
ICBT + IMRT CICBT IMRT-alone OICBT
GTV D90 (Gy) 103.5 ± 8.0 174.8 ± 52.8 88 ± 0.5 123 ± 23.3
t; p value t = 7.3; p = 0.00* t = 10.5; p = 0.00* t = 4.4; p = 0.00*
D100 (Gy) 84.7 ± 5.0 104.8 ± 27 81 ± 2.3 83.4 ± 4.9
t; p value t = 4.4; p = 0.00* t = 5.5; p = 0.00* t = 0.7; p = 0.45
IRCTV-pv D90 (Gy) 77.7 ± 0.9 65.6 ± 9.1 78.1 ± 0.8 58.7 ± 4.0
t; p value t = 7.1; p = 0.00* t = 1.5; p = 0.14 t = 23.4; p = 0.00*
D100 (Gy) 63.7 ± 2.4 53.3 ± 3.3 65.1 ± 2.7 50.4 ± 1.8
t; p value t = 14.7; p = 0.00* t = 2.4; p = 0.02* t = 25; p = 0.00*
V100 (%) 94.2 ± 1.9 74.1 ± 13.1 93.1 ± 2.5 60.5 ± 10.8
t; p value t = 11.0; p = 0.00* t = 2.6; p = 0.00* t = 22.7; p = 0.00*
HRCTV-pv D90 (Gy) 88.3 ± 1.8 105.9 ± 24.5 85.3 ± 0.9 85.5 ± 6.1
t; p value t = 4.0; p = 0.00* t = 7.8; p = 0.00* t = 2.5; p = 0.02*
D100 (Gy) 69.6 ± 6.6 63.9 ± 10.6 72.8 ± 2.0 62.1 ± 6.6
t; p value t = 2.8; p = 0.01* t = 1.2; p = 0.23 t = 9.3; p = 0.00*
V100 (%) 94.4 ± 2.8 93.5 ± 10.3 92.1 ± 1.6 89.4 ± 8.7
t; p value t = 0.6; p = 0.55 t = 5.5; p = 0.00* t = 4.1; p = 0.00*
*

Represents the level of statistical significance p < 0.05 (two tails).

ICBT – intracavitary brachytherapy, IMRT – intensity modulated radiation therapy, CICBT – 2D HDR intracavitary brachytherapy, OICBT – 3D optimized HDR intracavitary brachytherapy, GTV – gross tumor volume, IRCTV – intermediate risk clinical target volume, HRCTV – high risk clinical target volume, D100, D90 – the minimum dose to 100%, 90% of the CTV, V100 – the percent volume of the post-implant prostate receiving 100% of the prescribed dose.